O	0	10	Activation	Activation	NN	B-NP
O	10	11	-	-	HYPH	B-NP
O	11	18	induced	induce	VBN	I-NP
O	19	27	cytidine	cytidine	NN	I-NP
O	28	37	deaminase	deaminase	NN	I-NP
O	38	40	in	in	IN	B-PP
O	41	49	antibody	antibody	NN	B-NP
O	50	65	diversification	diversification	NN	I-NP
O	66	69	and	and	CC	O
B-Cellular_component	70	80	chromosome	chromosome	NN	B-NP
O	81	94	translocation	translocation	NN	I-NP
O	94	95	.	.	.	O

O	97	100	DNA	DNA	NN	B-NP
O	101	107	damage	damage	NN	I-NP
O	107	108	,	,	,	O
O	109	122	rearrangement	rearrangement	NN	B-NP
O	122	123	,	,	,	O
O	124	127	and	and	CC	O
O	128	136	mutation	mutation	NN	B-NP
O	137	139	of	of	IN	B-PP
O	140	143	the	the	DT	B-NP
O	144	149	human	human	JJ	I-NP
O	150	156	genome	genome	NN	I-NP
O	157	160	are	be	VBP	B-VP
O	161	164	the	the	DT	B-NP
O	165	170	basis	basis	NN	I-NP
O	171	173	of	of	IN	B-PP
O	174	188	carcinogenesis	carcinogenesis	NN	B-NP
O	189	192	and	and	CC	O
O	193	200	thought	think	VBN	B-VP
O	201	203	to	to	TO	I-VP
O	204	206	be	be	VB	I-VP
O	207	214	avoided	avoid	VBN	I-VP
O	215	217	at	at	IN	B-PP
O	218	221	all	all	DT	B-NP
O	222	227	costs	cost	NNS	I-NP
O	227	228	.	.	.	O

O	229	231	An	An	DT	B-NP
O	232	241	exception	exception	NN	I-NP
O	242	244	is	be	VBZ	B-VP
O	245	248	the	the	DT	B-NP
O	249	257	adaptive	adaptive	JJ	I-NP
B-Anatomical_system	258	264	immune	immune	JJ	I-NP
I-Anatomical_system	265	271	system	system	NN	I-NP
O	272	277	where	where	WRB	B-ADVP
B-Cell	278	289	lymphocytes	lymphocyte	NNS	B-NP
O	290	297	utilize	utilize	VBP	B-VP
O	298	308	programmed	program	VBN	I-VP
O	309	312	DNA	DNA	NN	B-NP
O	313	319	damage	damage	NN	I-NP
O	320	322	to	to	TO	B-PP
O	323	329	effect	effect	NN	B-NP
O	330	337	antigen	antigen	NN	I-NP
O	338	346	receptor	receptor	NN	I-NP
O	347	362	diversification	diversification	NN	I-NP
O	362	363	.	.	.	O

O	364	368	Both	Both	CC	O
B-Cell	369	370	B	B	NN	B-NP
O	371	374	and	and	CC	O
B-Cell	375	376	T	T	NN	B-NP
I-Cell	377	388	lymphocytes	lymphocyte	NNS	B-NP
O	389	398	diversify	diversify	VBP	B-VP
O	399	404	their	their	PRP$	B-NP
O	405	412	antigen	antigen	NN	I-NP
O	413	422	receptors	receptor	NNS	I-NP
O	423	430	through	through	IN	B-PP
O	431	435	RAG1	RAG1	NN	B-NP
O	435	436	/	/	SYM	B-NP
O	436	437	2	2	CD	I-NP
O	438	446	mediated	mediate	VBN	I-NP
O	447	460	recombination	recombination	NN	I-NP
O	460	461	,	,	,	O
O	462	465	but	but	CC	O
B-Cell	466	467	B	B	NN	B-NP
I-Cell	468	473	cells	cell	NNS	I-NP
O	474	481	undergo	undergo	VBP	B-VP
O	482	485	two	two	CD	B-NP
O	486	496	additional	additional	JJ	I-NP
O	497	506	processes	process	NNS	I-NP
O	506	507	-	-	HYPH	O
O	507	508	-	-	HYPH	B-NP
O	508	515	somatic	somatic	JJ	I-NP
O	516	529	hypermutation	hypermutation	NN	I-NP
O	530	531	(	(	(	O
O	531	534	SHM	SHM	NN	B-NP
O	534	535	)	)	)	O
O	536	539	and	and	CC	O
O	540	545	class	class	NN	B-NP
O	545	546	-	-	HYPH	O
O	546	552	switch	switch	NN	B-NP
O	553	566	recombination	recombination	NN	I-NP
O	567	568	(	(	(	O
O	568	571	CSR	CSR	NN	B-NP
O	571	572	)	)	)	O
O	572	573	,	,	,	O
O	574	578	both	both	DT	B-NP
O	579	588	initiated	initiate	VBN	B-VP
O	589	591	by	by	IN	B-PP
O	592	602	activation	activation	NN	B-NP
O	602	603	-	-	HYPH	O
O	603	610	induced	induce	VBN	B-NP
O	611	619	cytidine	cytidine	NN	I-NP
O	620	629	deaminase	deaminase	NN	I-NP
O	630	631	(	(	(	O
O	631	634	AID	AID	NN	B-NP
O	634	635	)	)	)	O
O	635	636	.	.	.	O

O	637	640	AID	AID	NN	B-NP
O	641	651	deaminates	deaminate	VBZ	B-VP
O	652	661	cytidines	cytidine	NNS	B-NP
O	662	664	in	in	IN	B-PP
O	665	668	DNA	DNA	NN	B-NP
O	669	678	resulting	result	VBG	B-VP
O	679	681	in	in	IN	B-PP
O	682	683	U	U	NN	B-NP
O	683	684	:	:	:	O
O	684	685	G	G	NN	B-NP
O	686	696	mismatches	mismatch	NNS	I-NP
O	697	701	that	that	WDT	B-NP
O	702	705	are	be	VBP	B-VP
O	706	715	processed	process	VBN	I-VP
O	716	720	into	into	IN	B-PP
O	721	726	point	point	NN	B-NP
O	727	736	mutations	mutation	NNS	I-NP
O	737	739	in	in	IN	B-PP
O	740	743	SHM	SHM	NN	B-NP
O	744	746	or	or	CC	O
O	747	753	double	double	JJ	B-NP
O	753	754	-	-	HYPH	I-NP
O	754	760	strand	strand	NN	I-NP
O	761	767	breaks	break	NNS	I-NP
O	768	770	in	in	IN	B-PP
O	771	774	CSR	CSR	NN	B-NP
O	774	775	.	.	.	O

O	776	784	Although	Although	IN	B-SBAR
O	785	788	AID	AID	NN	B-NP
O	789	797	activity	activity	NN	I-NP
O	798	800	is	be	VBZ	B-VP
O	801	808	focused	focus	VBN	I-VP
O	809	811	at	at	IN	B-PP
O	812	826	Immunoglobulin	Immunoglobulin	NN	B-NP
O	827	828	(	(	(	O
O	828	830	Ig	Ig	NN	B-NP
O	830	831	)	)	)	O
O	832	836	gene	gene	NN	B-NP
O	837	841	loci	locus	NNS	I-NP
O	841	842	,	,	,	O
O	843	845	it	it	PRP	B-NP
O	846	850	also	also	RB	B-ADVP
O	851	858	targets	target	VBZ	B-VP
O	859	860	a	a	DT	B-NP
O	861	865	wide	wide	JJ	I-NP
O	866	871	array	array	NN	I-NP
O	872	874	of	of	IN	B-PP
O	875	878	non	non	AFX	B-NP
O	878	879	-	-	HYPH	I-NP
O	879	881	Ig	Ig	NN	I-NP
O	882	887	genes	gene	NNS	I-NP
O	888	897	including	include	VBG	B-PP
O	898	907	oncogenes	oncogene	NNS	B-NP
O	908	918	associated	associate	VBN	B-VP
O	919	923	with	with	IN	B-PP
B-Cancer	924	933	lymphomas	lymphoma	NNS	B-NP
O	933	934	.	.	.	O

O	935	939	Here	Here	RB	B-ADVP
O	939	940	,	,	,	O
O	941	943	we	we	PRP	B-NP
O	944	950	review	review	VBP	B-VP
O	951	954	the	the	DT	B-NP
O	955	964	molecular	molecular	JJ	I-NP
O	965	970	basis	basis	NN	I-NP
O	971	973	of	of	IN	B-PP
O	974	977	AID	AID	NN	B-NP
O	978	988	regulation	regulation	NN	I-NP
O	988	989	,	,	,	O
O	990	999	targeting	targeting	NN	B-NP
O	999	1000	,	,	,	O
O	1001	1004	and	and	CC	O
O	1005	1015	initiation	initiation	NN	B-NP
O	1016	1018	of	of	IN	B-PP
O	1019	1022	CSR	CSR	NN	B-NP
O	1023	1026	and	and	CC	I-NP
O	1027	1030	SHM	SHM	NN	I-NP
O	1030	1031	,	,	,	O
O	1032	1034	as	as	RB	B-CONJP
O	1035	1039	well	well	RB	I-CONJP
O	1040	1042	as	as	IN	I-CONJP
O	1043	1046	AID	AID	NN	B-NP
O	1046	1047	'	'	POS	B-NP
O	1047	1048	s	s	JJ	I-NP
O	1049	1053	role	role	NN	I-NP
O	1054	1056	in	in	IN	B-PP
O	1057	1067	generating	generate	VBG	B-VP
B-Cellular_component	1068	1078	chromosome	chromosome	NN	B-NP
O	1079	1093	translocations	translocation	NNS	I-NP
O	1094	1098	that	that	WDT	B-NP
O	1099	1109	contribute	contribute	VBP	B-VP
O	1110	1112	to	to	TO	B-PP
O	1113	1128	lymphomagenesis	lymphomagenesis	NN	B-NP
O	1128	1129	.	.	.	O

